CD19 and acute lymphoblastic leukemia: In August 2017, the United States Food and Drug Administration (FDA) has approved the first CAR T cell therapy “Tisagenlecleucel”, a CD19 specific CAR construct, for the treatment of patients with RR B cell precursor acute lymphoblastic leukemia (ALL) (21).